Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis

Lushi Yu; Hongyun Gong; Qian Li; Honggang Ren; Yi Wang; Haihua He; Tian Li; Qibin Song

doi:10.1155/2021/8849039

Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis

J Oncol. 2021 Feb 11:2021:8849039. doi: 10.1155/2021/8849039. eCollection 2021.

Authors

Lushi Yu¹, Hongyun Gong¹, Qian Li¹, Honggang Ren¹, Yi Wang¹, Haihua He¹, Tian Li², Qibin Song¹

Affiliations

¹ Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.
² School of Basic Medicine Fourth Military Medical University/Air Force Medical University, Xi'an 710032, Shanxi, China.

Abstract

Results: A total of 20031 ovarian cancer patients were included, with 291 (1.45%) patients who received radiotherapy. The median overall survival (OS) in patients who received radiotherapy was shorter than which in patients without radiotherapy (23 vs. 75 months, P < 0.001). The Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. Among 11872 patients with III/IV stage, the radiotherapy group also showed a significantly worse prognosis (median OS: 19 vs. 44 months in patients without radiotherapy, P < 0.001). Consistent results were observed in stratification analyses on pathology and stage among patients with III/IV stage.

Conclusions: For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed.